XML 20 R9.htm IDEA: XBRL DOCUMENT
v3.25.2

License Agreements and Acquired Patent Applications | 6 Months Ended
--- | ---
Jun. 30, 2025
License Agreements and Acquired Patent Applications [Abstract] |
License Agreements and Acquired Patent Applications | NOTE 3 – License Agreements and Acquired Patent Applications The following summarizes the Company’s research and development expenses for licenses and patent applications acquired during the three and six months ended June 30, 2025 and 2024:
|  | For the Three Months Ended June 30, |  |  | For the Six Months Ended June 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
The George Washington University |  | $ | 1,250 |  |  | $ | 8,597 |  |  | $ | 2,500 |  |  | $ | 9,847 |
North Carolina State University |  |  | 938 |  |  |  | 1,563 |  |  |  | 1,875 |  |  |  | 3,125 |
University of Cincinnati |  |  | 2,708 |  |  |  | 417 |  |  |  | 3,333 |  |  |  | 417 |
Patent applications acquired |  |  | — |  |  |  | — |  |  |  | 1,250,500 |  |  |  | — |
|  | $ | 4,896 |  |  | $ | 10,577 |  |  | $ | 1,258,208 |  |  | $ | 13,389 |
The George Washington University During the three and six months ended June 30, 2025, the Company recorded expenses of $1,250 and $2,500, respectively, related to license fees pursuant to the patent license agreement with The George Washington University (“GW”) dated February 1, 2020 (“GW Patent License Agreement”) and the patent license agreement with GW dated August 7, 2020 (“Second GW Patent License Agreement”). During the three and six months ended June 30, 2024, the Company recorded expenses of $8,597 and $9,847, respectively, for license fees, including an expense of $6,389 and $6,389 for the three and six months ended June 30, 2024, respectively, related to warrants granted to GW pursuant to the GW Patent License Agreement and the Second GW Patent License Agreement. North Carolina State University During the three months ended June 30, 2025 and 2024, the Company recorded expenses of $938 and $1,563, respectively, for license fees associated with the license agreement by and between the Company and North Carolina State University dated February 25, 2021. During the six months ended June 30, 2025 and 2024, the Company recorded expenses of $1,875 and $3,125, respectively, for license fees associated with the license agreement by and between the Company and North Carolina State University dated February 25, 2021. Chelexa Biosciences, Inc. and the University of Cincinnati During the three months ended June 30, 2025 and 2024, the Company recognized expenses of $2,708 and $417, respectively, for license fees associated with the Assignment and Assumption Agreement by and between the Company and Chelexa Biosciences, Inc. dated May 14, 2020. During the six months ended June 30, 2025 and 2024, the Company recognized expenses of $3,333 and $417, respectively, for license fees associated with the Assignment and Assumption Agreement by and between the Company and Chelexa Biosciences, Inc. dated May 14, 2020. Patent Application Acquisition Agreement On January 13, 2025, the Company entered into a Patent Application Acquisition Agreement with Med30, LLC (the “Seller”), whereby the Seller sold, conveyed, assigned and transferred to the Company all of Seller’s right, title, and interest in and to certain patent applications and associated rights, subject to the terms and conditions set forth in such agreement for a cash payment of $400,000 and the issuance of 450,000 shares of the Company’s common stock with a fair value of $850,500 for an aggregate purchase price of $1,250,500. These common shares were valued at $850,500, or $1.89 per share, on the measurement date based on quoted closing price of the Company’s common stock. For asset acquisitions, in-process research and development (“IPRD”) is expensed immediately unless there is an alternative future use. The patent applications acquired do not constitute a business, as defined under ASU 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business (such when there is no substantive process in the acquired entity). The acquired IPRD intangible asset will be used in research and development projects which have been determined to not have alternative future use at the acquisition date and was expensed immediately. Accordingly, during the three and six months ended June 30, 2025, the Company recorded $0 and $1,250,500 in research and development expenses, respectively.

X
- Definition The entire disclosure of license agreements and acquired patent applications. + References No definition available. + Details
Name: | hoth_LicenseAgreementsAndAcquiredPatentApplicationsTextBlock
Namespace Prefix: | hoth_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNetAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration